These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 35183610)

  • 1. Decline of immune humoral response after BNT162b2 vaccine.
    Ferri S; Polidoro A; Ciacciarelli M; Ceratti U; Congedo V; Mele M; Coluzzi G; Spagnoli A; Iuliano L
    J Infect; 2022 Apr; 84(4):e34-e35. PubMed ID: 35183610
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
    Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():896151. PubMed ID: 35844588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
    Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
    Lancet Infect Dis; 2024 Feb; 24(2):e80-e81. PubMed ID: 38190833
    [No Abstract]   [Full Text] [Related]  

  • 7. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of humoral and cellular immunity in vaccinated with mRNA-1273.
    Gutiérrez-Bautista JF; López-Nevot MÁ; Gómez-Vicente E; Quesada T; Marín EM; Rodríguez A; Rodríguez AI; Rodríguez-Granger J; Cobo F; Sampedro A
    APMIS; 2022 May; 130(5):261-269. PubMed ID: 35196403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
    HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
    Candon S; Lemee V; Leveque E; Etancelin P; Paquin C; Carette M; Contentin N; Bobee V; Alani M; Cardinael N; Lepretre S; Camus V; Bouclet F; Boulet E; Menard AL; Lanic H; Stamatoullas A; Lemasle E; Pepin LF; Richard D; Dubois S; Tilly H; Dalleac A; Plantier JC; Etienne M; Jardin F
    Haematologica; 2022 Mar; 107(3):755-758. PubMed ID: 34854280
    [No Abstract]   [Full Text] [Related]  

  • 11. Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study.
    Zelini P; Isoletta E; Volontè M; Lilleri D; Cassaniti I; Musella V; Klersy C; Baldanti F; Brazzelli V
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e294-e296. PubMed ID: 36433886
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response.
    Masset C; Kerleau C; Garandeau C; Ville S; Cantarovich D; Hourmant M; Kervella D; Houzet A; Guillot-Gueguen C; Guihard I; Giral M; Dantal J; Blancho G
    Kidney Int; 2021 Nov; 100(5):1132-1135. PubMed ID: 34474075
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2.
    Bertram S; Blazquez-Navarro A; Seidel M; Hölzer B; Seibert FS; Doevelaar A; Rohn B; Zgoura P; Witte-Lack A; Skrzypczyk S; Scholten D; Kisters K; Babel N; Westhoff TH
    Sci Rep; 2022 Apr; 12(1):6243. PubMed ID: 35422075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
    Di Noia V; Pimpinelli F; Renna D; Campo F; Cosimati A; Torchia A; Marcozzi B; Massacci A; Pallocca M; Pellini R; Morrone A; Cognetti F
    Eur J Cancer; 2022 Nov; 176():164-167. PubMed ID: 36223679
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.